Day 1

Registration sponsored by GE Capital, Healthcare Financial Services

Sara Mueller, Executive Director, BioNetwork

• With many pre-clinical deals evolving away from straightforward, clean licensing deals with an asset in clinical trials, how are people successfully executing these types of deals?

• Creating common goals and outlining best practices for working side by side for a period of time to achieve these common goals

• How are other pharma firms optimizing collaboration, and how do they see collaboration and pre-clinical deals evolving in the near and far term?

• Describing the significance of the transaction and scope of the deal: RNA targeted, new chemistry, the clinical and research programs, and size

• Examining the historical perspective of the companies’ interactions and the initiation of discussions

• Outlining the courtship and due diligence period

• Understanding the competitive process as well as contract negotiations and closing the deal

• Investigating the current state of early stage funding; will pharma continue to move away from late stage investing and focus more on earlier stage partnerships?

• Examining the trend for pharma to supplement internal R&D investments with outside funding from major foundations

• What role is the US government playing in funding for drug discovery?

• What other sources are available to fund a commercial launch, including equity, venture debt, structured debt alternatives and more

• Outlining the importance of innovative public-private partnerships to support advancement

• Exploring the current state of academia and industry collaboration; how have these partnerships changed over the past year?

• Outlining success factors and opportunities for improvement on how academia and industry work together

• Ensuring you have the right long- and short-term plan in place for successful pharma/academia collaboration

• Exploring the differences, benefits, and detriments in partnering with big biotech vs. big pharma; what is best for your firm?

• What are big pharma and biotech looking for in their partner’s today, and how has this changed over the past year?

• Establishing the most effective methods for promoting your therapies or technology to ensure your deal is known

• Finding a partner for your firm: best practices and lessons learned

• Identifying different models and organizations around the world whose objectives are to support innovation and drug discovery

• Explaining how these models minimize risk for bringing a drug to market

• Determining the best way to get your company to partner with consortia like these; what are the benefits vs. detriments to your firm?

Have a cocktail and help us celebrate the first day of BioNetwork. Meet and network with new contacts as you take in views of the beautiful sunset over the Pacific Ocean